Progression of chronic renal failure in patients given ketoacids following amino acids  by Walser, Mackenzie et al.
Kidney International, Vol. 32 (1987), pp. 123—128
Progression of chronic renal failure in patients given ketoacids
following amino acids
MACKENZIE WALSER, NORMAN D. LAFRANCE, LYNNE WARD, and MARY ANN VANDUYN
Departments of Pharmacology and Molecular Sciences, Radiology, and Medicine, Johns Hopkins University School of Medicine, and the
Department of Nutrition, Johns Hopkins Hospital, Baltimore, Maryland, USA
Progresion of chronic renal failure in patients given ketoacids following
amino acids. Twelve patients with chronic renal failure who exhibited a
progressive decline in 24-hour creatinine clearance, despite being given
for 2 to 10 months a diet containing 0.3 g per kg ideal weight of protein
and 7 to 9 g mg per kg ideal weight of phosphorus, supplemented with
vitamins, CaCO3, and 10 g per day of essential amino acids, were
changed to a supplement containing predominantly ketoacids. In six
patients whose serum creatinine was 7.5 mgldl or greater at changeover,
progression continued unabated. In six patients with serum creatinine
levels at changeover of 6.6 to 7.4 mgldl, one was non-compliant with the
diet and progressed to dialysis. In the other five, progression, measured
as the rate of change of a bimonthly radioisotope clearance, has been
undetectable during the ensuing one to two years. There has been no
change in urea appearance, blood pressure, phosphaturia or protein-
uria. Nutrition has been maintained. Thus this ketoacid supplemented
regimen apparently halted the progression of moderately—severe
chronic renal failure for at least a year in a small group of patients in
whom restriction of protein and phosphate intake without ketoacids
failed to halt progression. In more severe renal failure, no effect on
progression was seen.
The first evidence that nutritional therapy might slow the
progression of chronic renal failure was reported in 1975 [1].
Among seven patients with severe chronic renal failure given a
low protein diet supplemented by calcium salts of ketoacids,
three showed improved renal function and three others did not
progress for several months. Four of the six had exhibited
progression during a prior period of essential amino acid
supplementation. One of these patients who had had a previous
course of hemodialysis remained in good health without dialysis
for 33 months [21.
Subsequent work [3—9] has supported the view that this
regimen may slow progression, but contrary views have also
been published [10, 11]. Others have reported [9, 12, 13] that
supplements of essential amino acids may slow progression
when added to a similar diet.
Recently we reported [14] that a mixture containing predom-
inantly branched—chain ketoacids as mixed salts of basic amino
acids, when given with the same diet, induced slowing or arrest
of progression in all of seven patients whose serum creatinine
was less than 8 mgldl. The relative importance of diet and
ketoacid supplements in slowing progression could not be
determined from these results. We have therefore compared
progression in patients given this diet before and during
ketoacid supplementation. Essential amino acids were admin-
istered during the control period to meet nutritional require-
ments.
Methods
Twelve patients with chronic renal faiure (Table 1) were
selected for study. Most were part of a study [15] of the effect
of diet plus essential amino—acid supplementation on progres-
sion; the twelve included in the present study were selected on
the basis that they were all progressing despite this regimen.
They have been divided into two groups, based on serum
creatinine concentrations at changeover from amino acid to
ketoacid supplements. They were given the diet described
below, 2.5 g per day of CaCO3, and vitamins. This regimen was
continued throughout the study. During the control period they
received a supplement of 10 gm per day of essential amino
acids, containing 1 g per day of nitrogen.1 During the experi-
mental period this was replaced by 18 g per day of ketoacidl
amino acid mixture "EE", previously described [14]. Mixed
salts of branched—chain ketoacids initially were prepared as
described previously [15], and later purchased from Ajinomoto
Co. (Teaneck, New Jersey). The nitrogen content of this
mixture is 1.8 g per day. Each batch of mixed salts was tested
for trace toxic impurities by injecting 5 mg/g body weight
intraperitoneally into ten mice and observing them for five days.
Both supplements were taken in three, divided daily doses
with meals. Essential amino acids were taken in capsules. The
ketoacid supplement was suspended in fruit juice.
Caloric prescription was derived from three—day diet diaries,
24-hour diet recall, and an estimate of basal energy expenditure
adjusted for activity [17]. The average prescription was 35 kcal
per kg of actual body weight (this was not modified because of
differences between actual weight and ideal body weight).
Mixed quality protein was prescribed at 0.3 g per kg ideal body
weight. Phosphorus was prescribed at 7 to 9 mg per kg ideal
body weight. To meet caloric needs, it was necessary to give 50
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'L-threonine, 9.0%; L-tryptophan, 2.4%; L-valine, 12.2%; L-
isoleucine, 9.9%; L-leucine, 17.1%, L-lysine acetate, 15.4%; L-methi-
onine, 10.8%; L-histidine, 4.1%; L-phenylalanine, 19.2%.
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Months of Serum [Cr]
treatment at
.Patient .Amino Keto changeover
age, race, sex Diagnosis acids acids mg/dl
Group I
AR, 57 WF Diabetic nephropathy 6 12 6.0
DO, 70 WM Chr. pyelonephritis 8 13 6.8
DU, 40 WM Chr. glomerulonephr. 5 18 6.8
HA, 57 WM Interstitial nephr. 10 27 7.3
MI, 61 WF Renal vascular dis. 9 5 6.5
OS, 76 WM Interstitial nephr. 8 12 7.4
Mean 8 15 6.8
SEM 1 3 0.2
Group II
BI, 71 WM Unknown 6 5 8.0
DE, 65 WF Nephrosclerosis 5 3 11.3
DL, 44 WM Lupus nephritis 6 3 9.7
RO, 61 WM Radiation nephritis 2 ia 7.5
SA, 36 WM IgA nephropathy 2 2 8.2
WE, 35 BM Chr. gtomerulonephr. 3 4 10.7
Mean 4 3 9.2
SEM 1 1 0.6
a Progressed to dialysis
to 100 g per day of a nitrogen—free maltodextrin supplement
(Maltrin, Grain Processing Corporation, Muscatine, Iowa,
USA) and also to provide special low—protein foods. Patients
were advised to use polyunsaturated fats. Fats provided about
40% of energy intake. Average dietary potassium was 65
mEq/day, except when hyperkalemia occurred; in these in-
stances potassium intake was decreased slightly, and a potas-
sium—binding resin was prescribed. Diets were designed to
accommodate each patient's preferences. All patients needed
dietary consultation at least three times, and some at every
visit. All patients received a vitamin—mineral preparation con-
taining no supplemental phosphorus (Theragran M), one tablet
per day. Despite the iron content of this supplement, all but one
patient required additional iron (usually as FeSO4) to prevent a
subnormal, plasma iron concentration. All but two patients
required salt restriction and received furosemide. Three pa-
tients were given supplemental zinc (as ZnSO4). Four patients
required sodium polystyrene sulfonate to prevent hyperkale-
mia, for unknown reasons. One patient received A1(OH)3 to
combat hyperphosphatemia. Anti-hypertensive drugs (hydrala-
zine, prazosin, clonidine, or metoprolol) were used in all but
two patients. None received angiotensin—converting enzyme
inhibitors, and none received any nephrotoxic drugs.
Patients were seen monthly before and after starting
ketoacids. Blood samples for routine chemical analyses were
obtained at each visit. In Group 1 patients, 24-hour urine
collections were obtained every one to three months, using a
cup of white vinegar as a preservative, and analyzed for urea,
creatinine, phosphate and protein. In Group I, radioisotope
clearances were measured every two months during ketoacid
supplementation only. In Group II, sufficient radioisotope
clearances for analysis were obtained in only one patient (BI).
Following a water load of 10 to 15 ml/kg and the ingestion of five
drops of a saturated solution of potassium iodide, 100 jsCi of
99mTc4abelled diethylenetriamine—pentaacetic acid was in-
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Fig. 1. Progression of chronic renalfailure in six patients whose serum
creatinine at changeover from amino acids to ketoacids was 7.5 mg per
dl or greater. Values for reciprocal serum creatinine concentration
decline at the same rate before and after changeover. Dialysis is
represented by vertical lines.
jected intravenously and 35 Ci of '251-labelled iothalamate was
injected subcutaneously. Beginning 60 minutes after the injec-
tions, three timed urine collections were obtained, along with
plasma samples, and urinary clearances were calculated and
averaged. Urine flow exceeded 0.8 ml per minute, As we have
noted elsewhere [181, the urinary clearances of these two
isotopes, measured in this manner, are nearly identical. Clear-
ances were not corrected for surface area.
Progression rates in Group I patients were calculated from
24-hour creatinine clearances measured at least monthly and
from bimonthly radioisotope clearances by least—squares linear
regression. In Group II patients, few 24-hour urines and even
fewer isotope clearances were obtained, because of the short
period of observation and the clinical condition of these sub-
jects. Consequently, progression in this group was estimated
from the rate of decline of the reciprocal of serum creatinine
concentration (tCr]') 1119]; in patient BI, sufficient radioisotope
clearances for analysis of progression were also available.
Results
Effects on progression
As shown in Figure 1, all six patients in Group II were
progressing on the amino acid supplement and continued to
progress at approximately the same rate on the ketoacid sup-
plement. Four have required dialysis, as shown. In patient BI,
linear regression analysis of sequential radioisotope GFR's
showed a progression rate of —0.18 0.22 ml per minute on
amino acids and —0.31 0.07 ml per minute on ketoacids, not
significantly different. There were no recognizable renal insults





























Fig. 2. Reciprocal serum creatinine concentrations versus time in six
patients whose serum creatinine at changeover from amino acids to
ketoacids was 7.4 mg per dl or less. Linear regression lines are shown,
but the relationships are non—linear in several cases. [CrI' tends to rise
and then fall on ketoacids in most subjects.
in this group of patients, and their blood pressure was not
significantly different on the two supplements (180 9/94 10
mm Hg on amino acids vs. 154 16 / 83 9 mm Hg on
ketoacids).
In contrast, Group I patients exhibited a marked retardation
of progression on changing from the amino acid supplement to
the ketoacid supplement. In Figure 2 are shown values for
[Cr ] before and after changing supplements. Linear regres-
sion lines are shown, but several of these relationships are
clearly non-linear or exhibit discontinuities. In Figure 3 are
shown the individual observations of 24-hour creatinine clear-
ance during both treatment periods. The radioisotope clear-
ances during the ketoacid period are shown in Figure 4. The
calculated regression lines are shown and the slopes and their
errors of the clearances are displayed in Table 2.
All six patients were progressing on the amino acid supple-
ment, as shown by significantly negative slopes of creatinine
clearance against time. On changing to ketoacids, the slopes of
creatinine clearance became significantly less negative except
in patient MI, who progressed to dialysis. A slow decline in
creatinine clearance was detectable in three patients (DO, DU
and HA), and an increase in one patient (OS). These changes,
though statistically significant by linear regression analysis, are
Fig. 3. Progression of chronic renal failure in the same patients as in
Figure 2, measured by 24-hour creatinine clearance. Linear regression
lines are shown. All patients were progressing on amino acids. Patient
MI continued to progress at approximately the same rate. Creatinine
clearance also declines very slowly during ketoacid supplementation in
patients DO, DU, and HA, but remains constant or rises in patients AR
and OS.
of doubtful biological significance, because the radioisotope
clearances in all five patients except MI are constant (Fig. 4 and
Table 2). The mean rate of change in these five patients is +0.01
0.04 ml min1 . mo. Furthermore, in at least one subject
(DO) the time course of creatinine clearance was not linear (Fig.
3) and the most recent creatinine clearance in this patient (7.4
mI/mm) was within the confidence limits (7.4 to 8.8 ml/min) of
the value at the start of ketoacids 15 months ago. These changes
in creatinine clearance may reflect effects of ketoacid supple-
mentation on tubular secretion of creatinine. The ratio of
creatinine clearance to isotopically determined GFR measured
the next day in these subjects was as follows: (means SD):
AR, 1.41 0.26; DO, 2.11 0.73; DU, 1.54 0.26; HA, 1.50
0.31; OS, 1.22 0.38; MI, 1.96 0.47.
Keto acids
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Rate of change of clearance, ml. min' month',
means + SEM, (no. of obs.)
Creatinine Isotopes
Patient Amino acids Keto acids Keto acids
Compliant patients
AR —1.48 0•40(4)b + 0.05 O.08(ll)a —0.06 0.07(7)
DO
—0.77 024(4)b —0.22 006(16)a.d +0.01 0.07(8)
DU —1.23 0.27(9)" —0.13 0.04(l7)a —0.03 0.06(8)
HA —0.22 004(11)" —0.05 0.02(37r" 0.00 0.04(8)
OS —0.80 0.21(4)c +0.28 0.09(8)aC +0.15 0.17(6)
Mean —0.90 0.22" —0.01 0.08a +0.01 0.04
Non-compliant patient
MI —1.23 038(7)b —1.10 0.33(7)c —0.36 0.14(4)
All patients
Mean —0.95 0.16" —0.17 0.17a —0.05 o.o7
Compliance
Dietary compliance in Group I patients was documented by
monthly measurement of 24-hour urinary excretion rates of
urea nitrogen and phosphate. As shown in Table 3, urea N
excretion rate averaged 4.2 0.3 g per day on amino acids and
5.1 0.4 g/day in five patients, but was nearly twice as great in
patient MI. The significant increase on switching to ketoacids is
attributable to the difference in N content, 0.8 g/day. Phosphate
excretion averaged 238 45 mg per day on amino acids and 291
44 mg per day on ketoacids in these five patients, but was two
to three times greater in patient MI. On the basis of these
observations in patient MI, which lie more than five standard
deviations from the mean of the other five patients, she was
judged to be noncompliant with the diet. She apparently com-
plied with the supplements, but this is uncertain.
Blood pressure and proteinuria
Since hypertension is believed to play a role in the progres-
sion of chronic renal failure [20], it was important to determine
whether better control of hypertension during the ketoacid
period could account for the results. As shown in Table 4, both
systolic and diastolic blood pressure were slightly but insignif-
icantly higher during ketoacid supplementation in Group I (as
noted above, there was no significant change in Group II).
Further indirect evidence against a change in the degree of
intrarenal hypertension was the absence of a significant change
in proteinuria in compliant patients (Table 3). In non-compliant
patient MI, proteinuria increased significantly, from 0.5 g per
day to 3.1 g per day.
Nutritional parameters
Body weight (Table 4), serum albumin and serum transferrin
were not significantly different between the two treatment
periods in Group I (Table 5) or Group II patients. The hemato-
crit fell, insignificantly in Group I (Table 4) but significantly in
Group II, reflecting their worsening azotemia. Urinary creati-
nine excretion is a measure of muscle mass in subjects with




























Creatinine 861 856 1101 1214
mg/day 75 60 101 79
Phosphate 238 291 790 779
mg/day 45 44 53 62
Protein 1189 839 539 3086b
mg/day 556 109 464
Urea N 4.2 5.l 8.5 8.7
g/day 0.3 1.0 0.2
patients with chronic renal failure [22]. Nevertheless,
creatininuria did not change significantly in Group I (Table 3) or
Group II. Serum cholesterol and triglyceride levels did not
change significantly in the compliant patients, but fell in patient
MI (Table 5).
Table 2. Comparison of rates of progression on amino acid


















a Significantly different from value observed on amino acids, P < 0.01
b Significantly different from zero, P < 0.05
Significantly different from zero, P < 0.025




5 10 15 20 25
Time, months
Fig. 4. Progression of chronic renal failure during ketoacid supple-
mentation in the same six patients shown in Figure 2, measured as
sequential radioisotopically determined GFR's. Only patient MI exhib-
its progression.
Table 3. Comparison of urinary excretion rates during amino acid
supplementation vs. ketoacid supplementation in Group I patients
a Significantly different from value on amino acids, P < 0.05
b Significantly different from value on amino acids, P < 0.025
Means SEM of five patients' mean values
d Means SEM of all observations in one patient
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Table 4. Comparison of observations during amino acid
supplementation with observations during ketoacid
supplementation in Group I patients
Compliant Non-compliant
patientsa patient"
Amino Keto Amino Keto
acids acids acids acids
Weight 68.4 67.6 79.3 78.8
kg 2.2 2.5 0.3 0.3
Systolic BP 154 165 157 175
mmHg 7 9 7 7
Diastolic BP 76 81 76 86
mmHg 7 7 3 2
Hematocrit 31 28 26 24
% 2 1 1 I
a Mean of five patients' mean values during treatment
b Mean of all observations in one patient
Other chemical values
Serum calcium and alkaline phosphatase levels did not
change, but serum phosphate rose slightly in all six Group I
patients (Table 5). Uric acid levels did not change significantly
(Table 5).
Other observations
Group II patients were all symptomatic and incapacitated to
varying degrees; only one was employed. The five compliant
Group I patients, despite an average glomerular filtration rate of
only 6.0 ml per minute, still remain nearly asymptomatic; three
are employed full time; the other two are retired but pursue
active lives. All five will admit to mild fatiguability, which may
be related to their anemia (average hematocrit 28%).
Discussion
These results show that a low protein, low phosphorus
regimen supplemented with ketoacids can virtually arrest the
downward course of chronic renal failure in some patients, for
at least one year, provided it is initiated soon enough. Although
a slow decline in creatinine clearance was detectable in three of
the compliant Group I patients, and a significant increase was
seen in a fourth, radioisotope clearance, which is more reliable,
was constant.
The results reported here are similar to those reported earlier
in patients on a free diet treated with ketoacids [14]. In that
study, five of seven patients treated with this same supplement
and a very similar diet before [Cr] reached 8 mg per dl had [Cr]
levels at or below this initial level an average of 22 months later;
among ten patients with initial [Cr]  8 mg per dl, this was true
of only one. The reason for this difference in response between
moderate and severe renal failure is not clear. We have ob-
served the same phenomenon in patients treated with essential
amino acids [15].
The present work separates the effects of the two compo-
nents of this regimen, diet and ketoacids. Since all patients were
previously progressing despite the diet, the slowing of progres-
sion we have observed must be attributed to the ketoacid
supplement. Dietary restriction, nevertheless, may be neces-
sary for this effect to occur, as suggested by the results in
patient MI. She continued to progress despite ketoacids, which
Table 5. Comparison of serum chemical values during amino acid
supplementation and ketoacid supplementation in Group I patients
Compliant Non-compliant
patientsa patient"
Amino Keto Amino Keto
Serum values acids acids acids acids
Calcium 9.7 9.2 9.2 8.6
mgldl 0.3 0.2
Phosphate 3.6 4.2c 5.8 6.4
mg/dl 0.1 0.3
Albumin 4.3 4.3 4.2 3.9
gidI
Transferrin 240 225 232 200
mg/dl 9
Alk. phosphatase 82 73 62 57
lU/liter 14 14 3 3
Uric acid 8.0 8.2 7.1 7.1
mg/dl 0.7 0.1
Cholesterol 186 176 225 201
mg/dl 28 28 9 5
Triglycerides 178 156 557 366C
mg/dl 19 28 39 18
a Mean of five patients' mean values during treatment
b Mean of all observations in one patient
Significantly different from mean on amino acids, P < 0.025
she probably consumed, but as shown by her 24-hour urine
collections, did not follow the diet. However, the data are
insufficient to conclude that this patient failed to respond owing
to non-compliance.
The possibility exists that the change in progression rate was
unrelated to the change in supplement. However, this seems
very unlikely. Spontaneous slowing of progression is only seen
in 10 to 12% of cases of chronic renal failure [23, 24]. A
crossover design would have been preferable, but patients
whose progression has apparently stopped are unlikely to
consent to a change of supplements. These problems could be
obviated by a randomized trial.
Nutrition was evidently well maintained, as assessed by body
weight, serum proteins, and urinary creatinine excretion. We
did not make anthropometric measurements because we have
found these to be unreproducible. Lucas et a! [8] have recently
reported that arm muscle circumference fell in a group of
patients given ketoacids for 6 to 12 months, even though there
was no change in the concentrations of serum albumin or
transferrin. However, body weight and creatinine excretion
also fell significantly in these patients. The probable explana-
tion is the more stringent protein restriction employed in their
study (0.2 g per kg body weight), supplemented by only 10 g of
ketoacid—amino acid mixture. Thus total intake of protein plus
supplement was only 24 g per 70 kg per day, in contrast to 39 g
per 70 kg per day in the regimen used herein. Why serum
protein levels did not fall in the face of probable protein
malnutrition is unclear. It is of interest to note that these
authors found some retardation of progression despite the fact
that all patients had initial [Cr] values over 7.8 mg per dl
(average 11.8 mg per dl).
The mechanism by which ketoacids slow progression is not
revealed by this work. Lowering of the circulating product of
free calcium ion and free phosphate ion, which might lessen a
tendency to renal calcification [25], is virtually excluded by the
finding that serum phosphate rose on the ketoacid supplement.
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This has apparently not been reported before and is not readily
explained. However, the increase was slight (0.6 mg per dl). A
change in intrarenal hypertension [26] is more difficult to
exclude, but neither blood pressure nor proteinuria decreased.
Dietary factors, such as whole protein or unsaturated fatty
acids [27] are excluded because the diet was constant before
and after progression stopped. Oxalate precursors [28] were
absent from both supplements. Chemical analyses of serum
gave no clues as to possible metabolic effects of ketoacids. Thus
further work will be necessary to elucidate the mechanism of
this effect.
Note added in proof
Since this article was submitted, one of the Group I patients (DO) has
progressed to dialysis, and a slow decline of radioisotope GFR (—0.062
0.025 ml mjn' mo) has become apparent in another (HA). The
average duration of ketoacid therapy in the five compliant Group I
patients is now 24 months.
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